A humanized monoclonal antibody directed against CD6, named Itoluzimab has recently been introduced and several clinical trials have now published preliminary data in several autoimmune diseases such as psoriasis47 and rheumatoid arthritis45. This evidence concerns the gene CD6 and autoimmune disease.